 BACKGROUND: thiazolidinediones (TZDs) improve tissue sensitivity insulin patients type II diabetes, resulting reduced levels fasting blood glucose glycated hemoglobin. However, TZDs unpredictably demonstrate adverse effects increased body weight, fluid retention, edema. balance efficacy safety TZD varies widely patient patient. Genetic variability may reveal pathophysiological pathways underlying weight gain associated TZD therapy due adiposity and/or edema. METHODS: analyzed 384 single nucleotide polymorphisms (SNPs) 222 cardiovascular metabolic genes 87 outpatients type 2 diabetes receiving thiazolidinedione therapy. Physiogenomic analysis used discover associations body mass index (BMI) edema. RESULTS: 5 significant gene associations found BMI SNPs ADORA1, adenosine A1 receptor (rs903361, p<0.0003), PKM2, pyruvate kinase-muscle (rs2856929, p<0.002); ADIPOR2, adiponectin receptor 2 (rs7975375, p<0.007); UCP2, uncoupling protein 2 (rs660339, p<0.008); APOH, apolipoprotein H (rs8178847, p<0.010). edema, 5 significant gene associations NPY, neuropeptide (rs1468271, p<0.006); GYS1, glycogen synthase 1-muscle (rs2287754, p<0.013); CCL2, chemokine C-C motif ligand 2 (rs3760396, p<0.015); OLR1, oxidized LDL receptor 1 (rs2742115, p<0.015); GHRH, growth hormone releasing hormone (rs6032470, p<0.023). accounting multiple comparisons, ADORA1 significantly associated BMI false discovery rate (FDR) <10%. CONCLUSION: Physiogenomic associations discovered suggesting mechanistic links adenosine signaling BMI, vascular permeability drug-induced edema.